IRLAB THERAP. AB A
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms … Read more
Market Cap & Net Worth: IRLAB THERAP. AB A (6IRA)
IRLAB THERAP. AB A (F:6IRA) has a market capitalization of $12.19 Million (€11.88 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #28684 globally and #3144 in its home market, demonstrating a -0.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IRLAB THERAP. AB A's stock price €0.14 by its total outstanding shares 84858244 (84.86 Million).
IRLAB THERAP. AB A Market Cap History: 2020 to 2026
IRLAB THERAP. AB A's market capitalization history from 2020 to 2026. Data shows change from $366.28 Million to $12.19 Million (-47.93% CAGR).
IRLAB THERAP. AB A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IRLAB THERAP. AB A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6IRA by Market Capitalization
Companies near IRLAB THERAP. AB A in the global market cap rankings as of March 18, 2026.
Key companies related to IRLAB THERAP. AB A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
IRLAB THERAP. AB A Historical Marketcap From 2020 to 2026
Between 2020 and today, IRLAB THERAP. AB A's market cap moved from $366.28 Million to $ 12.19 Million, with a yearly change of -47.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €12.19 Million | -19.54% |
| 2025 | €15.16 Million | -81.21% |
| 2024 | €80.66 Million | +33.43% |
| 2023 | €60.45 Million | -79.35% |
| 2022 | €292.67 Million | -16.73% |
| 2021 | €351.47 Million | -4.04% |
| 2020 | €366.28 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of IRLAB THERAP. AB A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.19 Million USD |
| MoneyControl | $12.19 Million USD |
| MarketWatch | $12.19 Million USD |
| marketcap.company | $12.19 Million USD |
| Reuters | $12.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.